BRIEF published on 08/28/2024 at 13:05, 1 year 11 months ago Rutherrin® Increases Efficacy of Chemotherapy for Lung Cancer Theralase® Technologies Inc. NSCLC Chemotherapy Rutherrin® Cisplatin
PRESS RELEASE published on 08/28/2024 at 13:00, 1 year 11 months ago Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer Theralase® announces significant enhancement of Cisplatin efficacy in chemotherapy resistant NSCLC using Rutherrin® drug formulation in preclinical studies. Combination therapy shows promising results for cancer treatment NSCLC Theralase Preclinical Studies Chemotherapy Rutherrin
BRIEF published on 08/21/2024 at 13:05, 1 year 11 months ago Theralase Demonstrates Activation of Rutherrin with Diabetes Drug Cancer Treatment Theralase Rutherrin Metformin ROS Production
BRIEF published on 08/21/2024 at 13:05, 1 year 11 months ago La théralase démontre l'activation de la rutherrine avec un médicament contre le diabète Traitement Du Cancer Theralase Rutherrin Metformine Production De ROS
PRESS RELEASE published on 08/21/2024 at 13:00, 1 year 11 months ago Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug Theralase Technologies Inc. announces innovative cancer treatment using Rutherrin activated by Metformin without light/radiation. Opens new patient care possibilities Innovation Theralase Technologies Inc. Cancer Treatment Rutherrin Metformin
BRIEF published on 08/12/2024 at 13:05, 2 years ago Theralase publie ses états financiers du deuxième trimestre 2024 Résultats Financiers Placements Privés Traitement Du Cancer Theralase Étude II
BRIEF published on 08/12/2024 at 13:05, 2 years ago Theralase Releases 2Q2024 Financial Statements Financial Results Private Placements Cancer Treatment Theralase Study II
PRESS RELEASE published on 08/12/2024 at 13:00, 2 years ago Theralase(R) Release’s 2Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the six-month period ended June 30, 2024. Conference call scheduled to review results. Study II progress and Break Through Designation update discussed Conference Call Financial Statements Theralase Technologies Inc. Break Through Designation Study II
BRIEF published on 07/08/2024 at 23:20, 2 years 1 month ago Theralase Closes $CAN 775,000 in First Tranche of Private Placement Private Placement Cancer Research Theralase Rutherrin Phase II Clinical Study
BRIEF published on 07/08/2024 at 23:20, 2 years 1 month ago Theralase clôture une première tranche de placement privé de 775 000 $CAN Placement Privé Recherche Contre Le Cancer Theralase Rutherrin Étude Clinique De Phase II
Published on 08/18/2026 at 02:20, 6 hours 6 minutes ago Numerous High-Grade Assays Extend Tolmer Silver Discovery
Published on 08/17/2026 at 22:30, 9 hours 56 minutes ago Matador Technologies Amends Convertible Note Facility to Expand At the Market Capacity and Commit a Fixed Share of Proceeds to Bitcoin
Published on 08/17/2026 at 21:00, 11 hours 26 minutes ago Taranis Announces New Critical Minerals By-Product Findings at the Thor and Ajax Mines
Published on 08/17/2026 at 15:00, 17 hours 26 minutes ago Norsemont Appoints Ariel Tepperman to Its Board
Published on 08/18/2026 at 08:13, 13 minutes ago Christoph Burkhard will become the new Chief Financial Officer of Heidelberger Druckmaschinen AG on October 1, 2026
Published on 08/18/2026 at 08:00, 26 minutes ago YOC AG Demonstrates Resilience in a Challenging Market Environment and Expects Increased Profitability Throughout the Remainder of 2026
Published on 08/18/2026 at 08:00, 26 minutes ago JDC Group AG continues its dynamic development in a challenging environment – revenues grow by 17% in the second quarter of 2026 (adjusted: 25.5%) – EBITDA increases by 83% (adjusted >100%)
Published on 08/18/2026 at 07:41, 45 minutes ago Einhell increases revenue and further expands the Power X-Change platform
Published on 08/18/2026 at 06:45, 1 hour 41 minutes ago The Medartis Group accelerates organic sales growth in H1 to 17.0% and achieves a core EBITDA margin of 18.0%
Published on 08/17/2026 at 19:45, 12 hours 41 minutes ago Aéroports de Paris S.A - July 2026 traffic figures
Published on 08/17/2026 at 19:45, 12 hours 41 minutes ago Aéroports de Paris S.A - Trafic du mois de juillet 2026
Published on 08/17/2026 at 17:45, 14 hours 41 minutes ago Déclaration hebdomadaire de rachat d'actions
Published on 08/17/2026 at 17:40, 14 hours 46 minutes ago Infotel : Déclaration des transactions sur actions propres réalisées du 10 au 14 août 2026 dans le cadre du programme de rachat d’actions.
